Jacobio Pharmaceuticals Group Co., Ltd. (Jacobio-B) disclosed that it repurchased 101,700 ordinary shares on 13 July 2026 via the Hong Kong Stock Exchange. The shares were bought at prices ranging from HK$4.90 to HK$4.92, for a volume-weighted average of HK$4.9036 per share, representing a total consideration of approximately HK$0.50 million.

Following the transaction: • Issued shares (excluding treasury) declined by 0.01% to 782.68 million. • Treasury shares increased to 9.07 million. • Total issued share capital remained unchanged at 791.76 million.

The buyback was executed under the repurchase mandate approved on 5 June 2026, which authorises the company to acquire up to 78.37 million shares. Cumulatively, Jacobio-B has repurchased 1.04 million shares, equal to 0.13% of the issued share base at the mandate date. Under Hong Kong listing rules, the company is subject to a moratorium on new share issues or treasury-share disposals until 12 August 2026.